Chakana Copper Corp. has elected to move from quarterly to semi-annual financial reporting under the Canadian Securities Administrators' Coordinated Blanket Order 51-933. This change applies because Chakana meets the criteria as a venture issuer with annual revenue under $10 million and a good disclosure record. The company will now file interim financial reports and management discussions twice a year, starting with the period ending August 31, 2026, while continuing annual audited reports and timely disclosure of material changes. This move aims to reduce reporting frequency while maintaining transparency for investors.
Chakana Copper's shift to semi-annual reporting is noted alongside Pluang's Basic Materials sector data. For readers following this sector, here is Pluang's market snapshot as of Oct 02, 2026 03:27 WIB: out of 38 priced US stocks, 7 rose and 30 fell today. Albemarle Corp. (ALB) traded at USD 104.55 with a typical hold time of 50 days and 100% buy order activity, LyondellBasell Industries NV (LYB) was at USD 57.52 with an 86-day hold time, and Air Products & Chemicals, Inc. (APD) stood at USD 273.38 with 58% sell order activity and a 60-day hold time.
Wells Fargo initiated coverage on BlackRock with an 'Overweight' rating, highlighting it as a good entry point for investors. Analysts expect BlackRock's Q3 earnings per share to rise to $14.25 from $11.55 a year ago, with revenue projected at $7.56 ...
Nike reported earnings per share of $0.48, beating estimates, but revenue fell short at $11.21 billion due to weak demand in Greater China and rising competition. The company issued a cautious fiscal 2027 outlook with EPS forecast between $1.15 and $...
NETSOL Technologies reported a record $20.7 million revenue in fiscal 2026 Q4, with net income rising 45.9% to $3.8 million. The company improved its gross margin to 63.6% and operating margin to 21.6%, reflecting enhanced profitability. For fiscal 2...
On October 1, 2026, Nexalin Technology surged 76.4% after securing a 10-year exclusive deal for its medical device in South America. Armada Acquisition Corp. II jumped 42.9% following shareholder approval of its merger with Evernorth, expected to clo...
Jefferies analyst Roger Song set a $150 price target for Nektar Therapeutics, suggesting a 219% upside from its $46.99 trading price. This comes after Nektar presented positive six-month Phase IIb trial results for its alopecia drug REZPEG, which als...
